SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the amended applications upper-limb data. Many interpret recent rare-disease discussions and commercial-launch job postings as encouraging signs, while skeptics point to the prior FDA setback and question whether the evidence will be sufficient; approval remains uncertain.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Golds sharp selloff, with GLD hitting a 52-week low, is tied in the discussion to inflation worries and expectations that interest rates may stay higher or rise. Traders debate whether gold has failed as a safe haven, while some see capitulation and a buying opportunity and others expect further losses.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A push to a fresh 52-week high is drawing attention ahead of an expected Q3 earnings update, while traders debate whether the rally reflects business momentum, short-covering, or speculation about an unconfirmed buyout.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has focused attention on the threat to Precigens PAPZIMEOS, its established therapy for the same condition. Traders are split on how much competition it poses, citing Precigens commercial head start and full approval versus Inovios potential treatment advantages and accelerated-approval requirements.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas stronger-than-expected quarterly results and raised outlook, alongside growing interest in identity security for AI agents, have driven a sharp rally. Traders are divided between seeing durable cybersecurity demand and warning that the move has outrun the companys growth, with valuation concerns and profit-taking weighing on shares.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff and fresh lows ahead of its earnings report are driving attention, with analyst price-target cuts and concerns about advertising demand adding pressure. Traders are split between viewing the decline as excessive given the companys growth and profitability, and worrying that weaker ad-market signals or an earnings disappointment could prolong the slide.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp technology selloff, as traders debate whether worries about AI spending and returns, alongside weakness in chip stocks, signal a deeper correction. The community is split between expecting more downside and viewing the drop as an oversold buying opportunity, with late-session rebounds fueling debate over whether a bottom is forming.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas early Baxfendy sales are prompting concern that aldosterone-synthase inhibitor drugs may ramp commercially more slowly than expected, weighing on MLYS despite no company-specific news behind the drop. Traders debate whether lorundrostat can overcome launch and competition risks, while some point to its upcoming FDA decision and clinical data as potential offsets.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians better-than-expected third-quarter results and raised full-year outlook have driven attention, with traders viewing the report as evidence of a turnaround and speculating about short covering. The bullish reaction is tempered by profit-taking and concerns about fuel costs, bookings, and the stocks post-surge volatility.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs quarterly update and recovery outlook are driving attention, with traders interpreting the restructuring reset as a possible sign that the worst is over and fueling talk of short covering. Others remain skeptical, citing weak demand, generic competition, heavy debt, and uncertainty about whether management can deliver the projected turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
